AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31129440
Drug: New KoCARC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New KoCARC TOR rules (combination of asystole and age > 60 years with current TOR rule)
Trial: 31129514
Drug: Vaccinated with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccinated with bi- or quadrivalent HPV vaccine
Trial: 31133863
Drug: Concurrent exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent exercise regimen (resistance exercise + functional exercise)
Trial: 31133899
Drug: Internet-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based intervention for depression, details on dosage and duration not available
Trial: 31136632
Drug: Anti-depressive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-depressive therapy
Trial: 31138229
Drug: PD-1 blockade
RxNorm normalized name: Recombinant pd-1 mab cs1003
DrugBank: Nofazinlimab (DB18852)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1 blockade (pembrolizumab) combined with radiation (3 × 8 Gy) and immune/environmental-targeting compounds (vitamin D, lansoprazole, aspirin, cyclophosphamide, curcumin)
Trial: 31138588
Drug: Pyrotinib 160
RxNorm normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrotinib 160 mg, 240 mg, 320 mg, or 400 mg once daily plus capecitabine 1,000 mg/m²
Trial: 31138588
Drug: Pyrotinib in
RxNorm normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrotinib in combination with capecitabine
Trial: 31139146
Drug: IVF treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVF treatment following POSEIDON criteria
Trial: 31139431
Drug: VR-CBT intervention
RxNorm normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VR-CBT intervention (8 weekly group sessions)
Trial: 31139441
Drug: No MAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No MAM treatment
Trial: 31139640
Drug: Fresh pomegranate
RxNorm normalized name: Pomegranate
DrugBank: Pomegranate (DB14317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fresh pomegranate juice (PJ) at 1.5 mL per kg body weight
Trial: 31139766
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg folic acid/d (higher strength)
Trial: 31139766
Drug: 0.8 mg
RxNorm normalized name: biotin 0.8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 mg folic acid/d (standard of care)
Trial: 31140667
Drug: Labels used
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labels used to describe themselves and when speaking with others who use drugs, with family and with treatment providers
Trial: 31142037
Drug: First-line triplet
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line triplet or doublet chemotherapy combined with targeted therapy
Trial: 31142450
Drug: Higher consumption
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher consumption of ultra-processed foods (>4 servings daily)
Trial: 31142503
Drug: CIV rhIL15
RxNorm normalized name: succinylcholine
DrugBank: Succinylcholine (DB00202)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIV rhIL15 at 2 μg/kg/day
Trial: 31142503
Drug: CIV rhIL15
RxNorm normalized name: succinylcholine
DrugBank: Succinylcholine (DB00202)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIV rhIL15 at various doses (0.125, 0.25, 0.5, 1, 2, or 4 μg/kg/day)
Trial: 31143880
Drug: Trabectedin (T)
DrugBank: Trabectedin (DB05109)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trabectedin (T) at dose level 1 (1.5 mg/m2) in combination with radiation therapy (RT) (45 Gy in 25 fractions of 1.8 Gy each)
Trial: 31145415
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of PF-06801591 at escalating doses (0.5, 1, 3, or 10 mg/kg) every 3 weeks
Trial: 31145415
Drug: Subcutaneous administration
RxNorm normalized name: subcutaneous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration of PF-06801591 at a single dose level of 300 mg every 4 weeks
Trial: 31145415
Drug: Overall response
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Overall response rate for both intravenous and subcutaneous administration
Trial: 31145415
Drug: Pharmacokinetics of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacokinetics of PF-06801591
Trial: 31145415
Drug: PD-1 receptor
RxNorm normalized name: Recombinant pd-1 mab cs1003
DrugBank: Nofazinlimab (DB18852)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1 receptor occupancy
Trial: 31147146
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy followed by concurrent cisplatin and radiation therapy (CRT)
Trial: 31147302
Drug: GLPG1837 (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLPG1837 (three increasing dosages twice-daily for two 7-day and one 14-day period)
Trial: 31148056
Drug: Conservative or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative or surgical treatment for LUTS/BPH
Trial: 31148336
Drug: RIP3 promoter
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RIP3 promoter variant rs3212247 CC genotype
Trial: 31151405
Drug: Intracoronary infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion of 25M pCPC
Trial: 31151405
Drug: Intracoronary infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion of 50M pCPC
Trial: 31151405
Drug: Intracoronary infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion of vehicle (Control)
Trial: 31152555
Drug: Artemether-lumefantrine administered
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemether-lumefantrine administered twice daily for 3 days
Trial: 31152705
Drug: REACH intervention
RxNorm normalized name: beach strawberry extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: REACH intervention (combined outpatient and home PT with app and tablet)
Trial: 31154457
Drug: Pembrolizumab, 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab, 200 mg, administered intravenously every 3 weeks for up to 35 doses.
Trial: 31154919
Drug: Pembrolizumab monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab monotherapy (2 mg/kg every 3 weeks or 10 mg/kg every 2 or 3 weeks)
Trial: 31154995
Drug: Counseling on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Counseling on appropriate infant feeding and WASH practices for six months (monthly visits)
Trial: 31155600
Drug: Quadrivalent HPV
RxNorm normalized name: HPV, quadrivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent HPV vaccine (qHPV), administered in a three-vaccination regimen (Day 1, Months 2 and 6)
Trial: 31156538
Drug: Parenteral Phenobarbital
RxNorm normalized name: Phenobarbital
DrugBank: Phenobarbital (DB01174)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral Phenobarbital
Trial: 31156538
Drug: Parenteral Phenytoin
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Parenteral Phenytoin
Trial: 31156861
Drug: Pharmacy care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacy care intervention involving motivational interviews, delivered by community pharmacists face-to-face or by telephone, as part of the New Medicine Service or a Medication Usage Review, lasting 15-20 minutes.
Trial: 31157039
Drug: Pharmaceutical care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical care programme focusing on resolving potential drug-related problems initiated at the emergency department
Trial: 31157074
Drug: 90 mM trisodium
RxNorm normalized name: TRISODIUM DIPHOSPHATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mM trisodium citrate solution
Trial: 31157074
Drug: 35 mM trisodium
RxNorm normalized name: TRISODIUM DIPHOSPHATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35 mM trisodium citrate solution
Trial: 31157074
Drug: Both 35 mM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both 35 mM and 90 mM trisodium citrate solutions
Trial: 31157746
Drug: Clarithromycin 500
RxNorm normalized name: clarithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 500 mg b.i.d. for 5 days
Trial: 31157864
Drug: CEASE intervention
RxNorm normalized name: BOIL-EASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEASE intervention with electronic tablet screener and motivational/educational videos; 2,764 smokers consented at visits.
Trial: 31157864
Drug: CEASE intervention
RxNorm normalized name: BOIL-EASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEASE intervention with electronic tablet screener; 2,764 smokers consented at visits.
Trial: 31159817
Drug: Statin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin treatment (157 patients)
Trial: 31160383
Drug: TAK-228 (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-228 (oral mTORC1/2 inhibitor) combined with TAK-117 (PI3Kα inhibitor)
Trial: 31160383
Drug: TAK-228 (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-228 (oral mTORC1/2 inhibitor) combined with paclitaxel (chemotherapy)
Trial: 31161044
Drug: Sliding hip
RxNorm normalized name: HIP
DrugBank: Heme iron polypeptide (DB11067)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sliding hip screw (SHS) and vitamin D supplementation (4000 IU daily for 6 months)
Trial: 31161044
Drug: Cancellous screws
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cancellous screws and vitamin D supplementation (4000 IU daily for 6 months)
Trial: 31164456
Drug: GC1118 (5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GC1118 (5.0 mg/kg)
Trial: 31164456
Drug: GC1118 (4.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GC1118 (4.0 mg/kg)
Trial: 31164456
Drug: GC1118 in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GC1118 in Cohort 1 (CRC without prior anti-EGFR treatment)
Trial: 31164456
Drug: GC1118 in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GC1118 in Cohort 2 (CRC with tumors resistant to anti-EGFR therapy)
Trial: 31164926
Drug: Liraglutide (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide (titrated from 0.6 mg q.d. to 1.8 mg q.d. over 4 weeks)
Trial: 31164926
Drug: Metformin (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (titrated from 500 mg b.i.d to 1000 mg b.i.d. over 4 weeks)
Trial: 31165541
Drug: Whole breast
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole breast once-weekly hypofractionated radiotherapy (wHF-RT) to a total dose of 30 Gy, in 5 fractions of 6 Gy
Trial: 31166857
Drug: Bacterial fluorescence
RxNorm normalized name: Fluorescein
DrugBank: Fluorescein (DB00693)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bacterial fluorescence imaging in combination with clinical evaluation of signs and symptoms (CSS)
Trial: 31167051
Drug: Intensive glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive glucose control (5.6 years of treatment)
Trial: 31167060
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no macrolide treatment)
Trial: 31167654
Drug: Once-weekly semaglutide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly semaglutide (0.5 and 1.0 mg)
Trial: 31167802
Drug: Oral idasanutlin
RxNorm normalized name: Idasanutlin
DrugBank: Idasanutlin (DB12325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral idasanutlin
Trial: 31167965
Drug: COL7A1-modified autologous
RxNorm normalized name: DNP-Modified autologous tumor vaccine
DrugBank: DNP-Modified autologous tumor vaccine (DB17436)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COL7A1-modified autologous fibroblasts (3 intradermal injections of ~1 × 10^6 cells/cm2)
Trial: 31168327
Drug: Adiponectin concentration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adiponectin concentration increase of 1 µg/mL
Trial: 31168494
Drug: Any other
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any other approved antiseizure drug (ASD)
Trial: 31170515
Drug: Radical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radical treatment options for higher risk prostate cancer
Trial: 31170941
Drug: Healthy Primary
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy Primary School of the Future (HPSF) initiative including daily free healthy lunches and structured physical activity sessions
Trial: 31171638
Drug: Red blood
RxNorm normalized name: Red blood cells
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red blood cell transfusion dose density
Trial: 31171735
Drug: Axitinib plus
RxNorm normalized name: Axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Axitinib plus Crizotinib (starting doses: axitinib 3 mg plus crizotinib 200 mg)
Trial: 31172977
Drug: Dolutegravir plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolutegravir plus boosted-darunavir dual therapy
Trial: 31174106
Drug: ICS/LABA/LAMA therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICS/LABA/LAMA therapy
Trial: 31174106
Drug: Liquid oxygen
RxNorm normalized name: OXYGEN 99 L in 100 L RESPIRATORY (INHALATION) GAS [Liquid Oxygen]
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liquid oxygen therapy
Trial: 31174106
Drug: ICS/LABA or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICS/LABA or ICS/LABA/LAMA associated therapy
Trial: 31175167
Drug: Regorafenib 160
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib 160 mg once daily for 3 weeks per 4-week cycle
Trial: 31177537
Drug: Vorinostat (SAHA),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vorinostat (SAHA), cladribine 5 mg/m², and rituximab (SCR)
Trial: 31177991
Drug: Intratumoral injections
RxNorm normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intratumoral injections of LTX-315 (oncolytic peptide)
Trial: 31178096
Drug: L-DOPA Monotherapy
RxNorm normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-DOPA Monotherapy
Trial: 31178096
Drug: Ineffective antidepressant
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ineffective antidepressant medication taper
Trial: 31179103
Drug: β-blockers (metoprolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β-blockers (metoprolol tartrate/metoprolol succinate/Bisoprolol Fumarate) within 24 hours of perioperative period
Trial: 31179103
Drug: Non-β-blockers
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-β-blockers
Trial: 31179386
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept (IVT-AFL) with loading dose
Trial: 31180977
Drug: Opioid dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid dosage
Trial: 31180977
Drug: Opioid use/dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid use/dosage
Trial: 31183469
Drug: Drug choices
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug choices for sedation; midazolam was the most preferred agent (90.0%).
Trial: 31183813
Drug: Eltrombopag (25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltrombopag (25, 50, 75, or 100 mg once daily)
Trial: 31183813
Drug: Eltrombopag (continued
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltrombopag (continued treatment)
Trial: 31183813
Drug: Eltrombopag (discontinued
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltrombopag (discontinued treatment)
Trial: 31183877
Drug: Hu5F9-G4 (anti-CD47
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hu5F9-G4 (anti-CD47 monoclonal antibody)
Trial: 31185735
Drug: Antianginal medication
RxNorm normalized name: ANTIANGINALS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antianginal medication escalation
Trial: 31185735
Drug: Antianginal medication
RxNorm normalized name: ANTIANGINALS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antianginal medication de-escalation
Trial: 31185735
Drug: No change
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No change in antianginal medications
Trial: 31187454
Drug: Intrathecal VTS-270
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal VTS-270 at doses of 50, 200, 300, or 400 mg per month, escalated to 600 or 1200 mg as tolerated.
Trial: 31189673
Drug: Titration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titration of circulating anti-HPV antibodies
Trial: 31189673
Drug: Weekly self-samples
RxNorm normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly self-samples for HPV monitoring
Trial: 31190006
Drug: Bendamustine 225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendamustine 225 mg/m²
Trial: 31190006
Drug: High-dose melphalan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose melphalan (MEL200)
Trial: 31190276
Drug: Eribulin 1.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eribulin 1.4 mg/m² combined with carboplatin (AUC 5 or 6 mg/mL·min)
Trial: 31190276
Drug: Eribulin 1.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eribulin 1.1 mg/m² combined with carboplatin (AUC 5 or 6 mg/mL·min)
Trial: 31190298
Drug: Intravenous fosfomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous fosfomycin (IV) administered at an average daily dose of 13.7±3.5 g over 12.4±8.6 days, almost exclusively in combination with other antibiotics.
Trial: 31191007
Drug: Simotinib, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simotinib, a novel specific EGFR tyrosine kinase inhibitor, dosage and duration not specified.
Trial: 31191235
Drug: High-definition transcranial
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-definition transcranial direct current stimulation (HD-tDCS) - 20 daily sessions, 1 mA, 20 min, 4 mm ring radius.
Trial: 31191908
Drug: Surveys administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surveys administered in the clinic post-visit to measure CKD-specific health literacy and trust in physician care.
Trial: 31192894
Drug: Daily Oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily Oral TDF/FTC PrEP
Trial: 31193095
Drug: Medical nutrition
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical nutrition therapy
Trial: 31193580
Drug: Centralized vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Centralized vaccine reminder/recall (R/R) via autodialed telephone and mail, up to 3 reminders.
Trial: 31193620
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose mebendazole
Trial: 31193620
Drug: Multiple dose
RxNorm normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple dose mebendazole
Trial: 31193674
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g dose of multi-OIT
Trial: 31193674
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg dose of multi-OIT
Trial: 31193674
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg dose (discontinuation of multi-OIT)
Trial: 31194225
Drug: Niraparib 200
RxNorm normalized name: niraparib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niraparib 200 mg orally once daily plus Pembrolizumab 200 mg intravenously on day 1 of each 21-day cycle
Trial: 31194228
Drug: Niraparib 200
RxNorm normalized name: niraparib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niraparib 200 mg orally once daily and Pembrolizumab 200 mg intravenously on day 1 of each 21-day cycle
Trial: 31194228
Drug: Niraparib in
RxNorm normalized name: Product containing niraparib in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niraparib in combination with Pembrolizumab
Trial: 31194611
Drug: Nivolumab in
RxNorm normalized name: nivolumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab in cohort B (prior therapy)
Trial: 31194939
Drug: Daily food
RxNorm normalized name: food
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily food choices
Trial: 31195062
Drug: Sofosbuvir/velpatasvir (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir/velpatasvir (400 mg/100 mg) once daily for 12 weeks
Trial: 31196083
Drug: Self-report questionnaires
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-report questionnaires assessing medication adherence (CQR)